Recursion

About Recursion

Financials

Dated, source-cited figures. Estimates are marked.

Products by Recursion

All products by Recursion reviewed by our AI panel of experts.

RecursionMachine Learning Platforms

AI-powered drug discovery at biological scale

Free7.4/10

How Our Review Panel Scores Recursion

Six independent reviewer personalities assessed Recursion's product on their own terms. They disagreed by 2.0 points — The Finance Lead was the hardest to convince, The Domain Strategist the most positive.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Recursion competes with, and how they differ.

Insilico Medicine7.7/10

Runs its own generative-AI drug-design pipeline (Chemistry42/PandaOmics) and has already advanced multiple self-discovered candidates into clinical trials, competing head-to-head with Recursion's automated discovery-to-clinic platform.

1 product reviewed on TopReviewed

I

Isomorphic Labs

A DeepMind spinout applying AlphaFold-derived structure prediction to drug design, backed by Google/Alphabet and large pharma partnerships (Eli Lilly, Novartis), competing for the same AI-native drug-discovery positioning with a stronger structural-biology pedigree.

I

Insitro

Combines machine learning with in-house wet-lab data generation (its "dataome" approach) focused on specific disease areas rather than Recursion's broad phenomics screening across thousands of cell models.

S

Schrodinger, Inc.

A publicly traded (Nasdaq: SDGR) physics-based computational chemistry platform licensed to pharma partners as software, versus Recursion's fully integrated wet-lab-plus-AI drug discovery and development pipeline.

Company Timeline

Key milestones in Recursion's history, with sources.

1. Nov 20, 2024Acquisition

   Exscientia merger closes

   Recursion completed its business combination with Exscientia; Exscientia became a wholly owned subsidiary of Recursion and its ADSs (Nasdaq: EXAI) delisted, with the combined company retaining the Recursion name and Nasdaq listing (RXRX) under continuing CEO Chris Gibson.

   marketscreener.com
2. Aug 8, 2024Acquisition

   Agrees to $688M all-stock merger with Exscientia

   Recursion entered a definitive agreement to merge with fellow AI-driven drug discovery company Exscientia in an all-stock deal valued at $688 million; Exscientia shareholders were to receive 0.7729 Recursion shares per share, ending with approximately 26% of the combined company.

   pharmaphorum.com
3. Apr 16, 2021Milestone

   IPOs on Nasdaq under RXRX

   Recursion Pharmaceuticals priced its IPO at $18.00 per share and began trading on the Nasdaq Global Select Market under "RXRX," raising gross proceeds of $501.8 million including the underwriters' option.

   sec.gov
4. Sep 9, 2020Funding

   Raises $239M Series D, partners with Bayer

   Recursion raised an oversubscribed $239 million Series D led by Leaps by Bayer and entered a strategic collaboration with Bayer to discover treatments for fibrotic diseases of the lung, kidney and heart, a deal potentially worth more than $1 billion in milestone payments.

   fiercebiotech.com
5. Nov 4, 2013Founded

   Blake Borgeson, Chris Gibson and Dean Li found Recursion

   Chris Gibson, Blake Borgeson and Dean Li founded Recursion Pharmaceuticals in Salt Lake City, building an automated, machine-learning-driven drug discovery platform out of research from the University of Utah.

   utahbusiness.com